Skip to main content
. 2019 Jun 20;36(8):1922–1935. doi: 10.1007/s12325-019-01003-7

Fig. 3.

Fig. 3

Impact of SxTox on total R/R episode costs. Note: exponentiated parameter estimates shown represent the multiplicative effect of the variable level compared with the reference (ref.) level (e.g., the exponentiated parameter estimate of 3.62 for the blood and lymphatic system disorders variable translates to 262% higher costs in patients with blood and lymphatic system disorders compared with patients without blood and lymphatic system disorders). Patients without the specific SxTox variable reported served as the reference group for each SxTox category